Drug Approval | December 23, 2025
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Full approval will depend on verification of clinical benefit in a confirmatory trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The company also reported significant progress toward its internally defined Sustainable Development Goals
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Subscribe To Our Newsletter & Stay Updated
